iRadimed (IRMD) Competitors

$86.89 +1.62 (+1.90%)

Closing price 04:00 PM Eastern

Extended Trading

$86.86 -0.03 (-0.04%)

As of 05:42 PM Eastern

IRMD vs. NVST, IRTC, LQDA, TMDX, and MMED

Should you buy iRadimed stock or one of its competitors? MarketBeat compares iRadimed with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with iRadimed include Envista (NVST), iRhythm Technologies (IRTC), Liquidia (LQDA), TransMedics Group (TMDX), and MiniMed Group (MMED). These companies are all part of the "medical equipment" industry.

How does iRadimed compare to Envista?

iRadimed (NASDAQ:IRMD) and Envista (NYSE:NVST) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, valuation, institutional ownership, profitability and risk.

iRadimed has a beta of 0.9, suggesting that its share price is 10% less volatile than the broader market. Comparatively, Envista has a beta of 0.92, suggesting that its share price is 8% less volatile than the broader market.

iRadimed currently has a consensus price target of $120.00, suggesting a potential upside of 38.11%. Envista has a consensus price target of $28.83, suggesting a potential upside of 21.00%. Given iRadimed's stronger consensus rating and higher probable upside, equities research analysts plainly believe iRadimed is more favorable than Envista.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iRadimed	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00
Envista	0 Sell rating(s)	9 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40

92.3% of iRadimed shares are held by institutional investors. 36.8% of iRadimed shares are held by insiders. Comparatively, 1.0% of Envista shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Envista had 1 more articles in the media than iRadimed. MarketBeat recorded 10 mentions for Envista and 9 mentions for iRadimed. Envista's average media sentiment score of 0.56 beat iRadimed's score of 0.43 indicating that Envista is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iRadimed	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Envista	4 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Envista has higher revenue and earnings than iRadimed. iRadimed is trading at a lower price-to-earnings ratio than Envista, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iRadimed	$86.28M	12.87	$22.48M	$1.83	47.48
Envista	$2.81B	1.38	$47M	$0.41	58.12

iRadimed has a net margin of 27.36% compared to Envista's net margin of 2.41%. iRadimed's return on equity of 24.48% beat Envista's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iRadimed	27.36%	24.48%	21.25%
Envista	2.41%	7.11%	3.91%

Summary

iRadimed beats Envista on 10 of the 17 factors compared between the two stocks.

How does iRadimed compare to iRhythm Technologies?

iRadimed (NASDAQ:IRMD) and iRhythm Technologies (NASDAQ:IRTC) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, valuation, profitability, dividends, earnings and media sentiment.

92.3% of iRadimed shares are owned by institutional investors. 36.8% of iRadimed shares are owned by company insiders. Comparatively, 1.0% of iRhythm Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

iRadimed has a beta of 0.9, suggesting that its share price is 10% less volatile than the broader market. Comparatively, iRhythm Technologies has a beta of 1.33, suggesting that its share price is 33% more volatile than the broader market.

iRadimed currently has a consensus price target of $120.00, indicating a potential upside of 38.11%. iRhythm Technologies has a consensus price target of $193.38, indicating a potential upside of 69.40%. Given iRhythm Technologies' higher possible upside, analysts clearly believe iRhythm Technologies is more favorable than iRadimed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iRadimed	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00
iRhythm Technologies	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.93

iRadimed has a net margin of 27.36% compared to iRhythm Technologies' net margin of -3.53%. iRadimed's return on equity of 24.48% beat iRhythm Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iRadimed	27.36%	24.48%	21.25%
iRhythm Technologies	-3.53%	-10.26%	-1.39%

iRadimed has higher earnings, but lower revenue than iRhythm Technologies. iRhythm Technologies is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iRadimed	$86.28M	12.87	$22.48M	$1.83	47.48
iRhythm Technologies	$787.85M	4.76	-$44.55M	-$0.86	N/A

In the previous week, iRadimed had 4 more articles in the media than iRhythm Technologies. MarketBeat recorded 9 mentions for iRadimed and 5 mentions for iRhythm Technologies. iRhythm Technologies' average media sentiment score of 1.47 beat iRadimed's score of 0.43 indicating that iRhythm Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iRadimed	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
iRhythm Technologies	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

iRadimed beats iRhythm Technologies on 11 of the 17 factors compared between the two stocks.

How does iRadimed compare to Liquidia?

iRadimed (NASDAQ:IRMD) and Liquidia (NASDAQ:LQDA) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, media sentiment, analyst recommendations, dividends and profitability.

iRadimed has higher earnings, but lower revenue than Liquidia. iRadimed is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iRadimed	$86.28M	12.87	$22.48M	$1.83	47.48
Liquidia	$288.07M	18.31	-$68.92M	$0.14	423.57

iRadimed has a net margin of 27.36% compared to Liquidia's net margin of 7.74%. Liquidia's return on equity of 46.82% beat iRadimed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iRadimed	27.36%	24.48%	21.25%
Liquidia	7.74%	46.82%	7.06%

iRadimed has a beta of 0.9, suggesting that its stock price is 10% less volatile than the broader market. Comparatively, Liquidia has a beta of 0.41, suggesting that its stock price is 59% less volatile than the broader market.

In the previous week, Liquidia had 44 more articles in the media than iRadimed. MarketBeat recorded 53 mentions for Liquidia and 9 mentions for iRadimed. Liquidia's average media sentiment score of 0.56 beat iRadimed's score of 0.43 indicating that Liquidia is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iRadimed	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Liquidia	15 Very Positive mention(s)	6 Positive mention(s)	13 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

iRadimed presently has a consensus price target of $120.00, indicating a potential upside of 38.11%. Liquidia has a consensus price target of $49.33, indicating a potential downside of 16.81%. Given iRadimed's stronger consensus rating and higher possible upside, equities analysts clearly believe iRadimed is more favorable than Liquidia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iRadimed	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00
Liquidia	2 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	2.92

92.3% of iRadimed shares are held by institutional investors. Comparatively, 64.5% of Liquidia shares are held by institutional investors. 36.8% of iRadimed shares are held by company insiders. Comparatively, 25.6% of Liquidia shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

iRadimed beats Liquidia on 9 of the 17 factors compared between the two stocks.

How does iRadimed compare to TransMedics Group?

TransMedics Group (NASDAQ:TMDX) and iRadimed (NASDAQ:IRMD) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, dividends, risk, earnings, valuation and institutional ownership.

TransMedics Group presently has a consensus target price of $135.00, suggesting a potential upside of 117.60%. iRadimed has a consensus target price of $120.00, suggesting a potential upside of 38.11%. Given TransMedics Group's higher possible upside, research analysts plainly believe TransMedics Group is more favorable than iRadimed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TransMedics Group	0 Sell rating(s)	6 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50
iRadimed	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00

TransMedics Group has a beta of 2.07, suggesting that its stock price is 107% more volatile than the broader market. Comparatively, iRadimed has a beta of 0.9, suggesting that its stock price is 10% less volatile than the broader market.

In the previous week, TransMedics Group had 1 more articles in the media than iRadimed. MarketBeat recorded 10 mentions for TransMedics Group and 9 mentions for iRadimed. iRadimed's average media sentiment score of 0.43 beat TransMedics Group's score of 0.15 indicating that iRadimed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TransMedics Group	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
iRadimed	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

iRadimed has a net margin of 27.36% compared to TransMedics Group's net margin of 27.04%. iRadimed's return on equity of 24.48% beat TransMedics Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TransMedics Group	27.04%	22.38%	8.46%
iRadimed	27.36%	24.48%	21.25%

TransMedics Group has higher revenue and earnings than iRadimed. TransMedics Group is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TransMedics Group	$635.89M	3.37	$190.29M	$4.40	14.10
iRadimed	$86.28M	12.87	$22.48M	$1.83	47.48

99.7% of TransMedics Group shares are held by institutional investors. Comparatively, 92.3% of iRadimed shares are held by institutional investors. 6.9% of TransMedics Group shares are held by insiders. Comparatively, 36.8% of iRadimed shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

iRadimed beats TransMedics Group on 9 of the 17 factors compared between the two stocks.

How does iRadimed compare to MiniMed Group?

iRadimed (NASDAQ:IRMD) and MiniMed Group (NASDAQ:MMED) are both medical equipment companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

iRadimed has higher earnings, but lower revenue than MiniMed Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iRadimed	$86.28M	12.87	$22.48M	$1.83	47.48
MiniMed Group	$2.99B	1.04	N/A	N/A	N/A

92.3% of iRadimed shares are held by institutional investors. Comparatively, 19.7% of MiniMed Group shares are held by institutional investors. 36.8% of iRadimed shares are held by company insiders. Comparatively, 2.2% of MiniMed Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, iRadimed had 5 more articles in the media than MiniMed Group. MarketBeat recorded 9 mentions for iRadimed and 4 mentions for MiniMed Group. MiniMed Group's average media sentiment score of 1.37 beat iRadimed's score of 0.43 indicating that MiniMed Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iRadimed	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MiniMed Group	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

iRadimed has a net margin of 27.36% compared to MiniMed Group's net margin of 0.00%. iRadimed's return on equity of 24.48% beat MiniMed Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iRadimed	27.36%	24.48%	21.25%
MiniMed Group	N/A	N/A	N/A

iRadimed currently has a consensus target price of $120.00, suggesting a potential upside of 38.11%. MiniMed Group has a consensus target price of $22.25, suggesting a potential upside of 100.81%. Given MiniMed Group's higher possible upside, analysts plainly believe MiniMed Group is more favorable than iRadimed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iRadimed	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00
MiniMed Group	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.93

Summary

iRadimed beats MiniMed Group on 8 of the 12 factors compared between the two stocks.

Get iRadimed News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IRMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IRMD vs. The Competition

Export

Metric	iRadimed	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.11B	$6.69B	$6.29B	$12.46B
Dividend Yield	0.95%	1.72%	2.79%	5.30%
P/E Ratio	47.48	49.56	20.89	25.59
Price / Sales	12.87	43.31	522.17	62.83
Price / Cash	45.59	24.21	42.94	55.34
Price / Book	11.27	6.50	9.86	6.70
Net Income	$22.48M	$158.34M	$3.55B	$333.77M
7 Day Performance	0.17%	-2.49%	-0.32%	0.45%
1 Month Performance	-7.13%	-1.89%	1.33%	4.06%
1 Year Performance	67.39%	-1.84%	41.10%	36.24%

iRadimed Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IRMD iRadimed	2.8728 of 5 stars	$86.89 +1.9%	$120.00 +38.1%	+60.2%	$1.11B	$86.28M	47.48	110	Insider Trade
NVST Envista	3.4662 of 5 stars	$25.99 +0.7%	$28.25 +8.7%	+28.0%	$4.25B	$2.72B	93.06	12,000	Analyst Downgrade
IRTC iRhythm Technologies	4.3974 of 5 stars	$117.40 -1.5%	$193.38 +64.7%	-18.0%	$3.84B	$787.85M	N/A	2,400	Positive News
LQDA Liquidia	2.6827 of 5 stars	$38.99 +1.3%	$43.44 +11.4%	+260.2%	$3.46B	$158.32M	N/A	50	Trending News Earnings Report Analyst Forecast Insider Trade Analyst Revision
TMDX TransMedics Group	4.3634 of 5 stars	$96.73 -0.4%	$152.33 +57.5%	-47.4%	$3.36B	$605.49M	19.83	210

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IRMD) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

iRadimed (IRMD) Competitors

IRMD vs. NVST, IRTC, LQDA, TMDX, and MMED

How does iRadimed compare to Envista?

Summary

How does iRadimed compare to iRhythm Technologies?

Summary

How does iRadimed compare to Liquidia?

Summary

How does iRadimed compare to TransMedics Group?

Summary

How does iRadimed compare to MiniMed Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IRMD vs. The Competition

iRadimed Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

iRadimed (IRMD) Competitors

IRMD vs. NVST, IRTC, LQDA, TMDX, and MMED

How does iRadimed compare to Envista?

Which has more risk & volatility, IRMD or NVST?

Do analysts prefer IRMD or NVST?

Do institutionals & insiders hold more shares of IRMD or NVST?

Does the media favor IRMD or NVST?

Which has preferable valuation & earnings, IRMD or NVST?

Is IRMD or NVST more profitable?

Summary

How does iRadimed compare to iRhythm Technologies?

Do insiders and institutionals believe in IRMD or IRTC?

Which has more volatility & risk, IRMD or IRTC?

Do analysts rate IRMD or IRTC?

Is IRMD or IRTC more profitable?

Which has stronger valuation & earnings, IRMD or IRTC?

Does the media refer more to IRMD or IRTC?

Summary

How does iRadimed compare to Liquidia?

Which has stronger valuation and earnings, IRMD or LQDA?

Is IRMD or LQDA more profitable?

Which has more volatility and risk, IRMD or LQDA?

Does the media favor IRMD or LQDA?

Do analysts rate IRMD or LQDA?

Do institutionals & insiders have more ownership in IRMD or LQDA?

Summary

How does iRadimed compare to TransMedics Group?

Do analysts prefer TMDX or IRMD?

Which has more risk and volatility, TMDX or IRMD?

Does the media prefer TMDX or IRMD?

Is TMDX or IRMD more profitable?

Which has preferable earnings & valuation, TMDX or IRMD?

Do insiders & institutionals have more ownership in TMDX or IRMD?

Summary

How does iRadimed compare to MiniMed Group?

Which has better earnings & valuation, IRMD or MMED?

Do insiders and institutionals have more ownership in IRMD or MMED?

Does the media refer more to IRMD or MMED?

Is IRMD or MMED more profitable?

Do analysts prefer IRMD or MMED?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IRMD vs. The Competition

iRadimed Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools